Last update 28 Jul 2025

Ixekizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Ixekizumab (Genetical Recombination), Ixekizumab (genetical recombination) (JAN), Ixekizumab (USAN)
+ [5]
Target
Action
inhibitors
Mechanism
IL-17A inhibitors(Interleukin 17A inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (22 Mar 2016),
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10071Ixekizumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Spondylarthritis
Canada
11 Aug 2016
Erythrodermic psoriasis
Japan
04 Jul 2016
Psoriasis
Japan
04 Jul 2016
Psoriasis vulgaris
Japan
04 Jul 2016
Pustular psoriasis
Japan
04 Jul 2016
Ankylosing Spondylitis
European Union
25 Apr 2016
Ankylosing Spondylitis
Iceland
25 Apr 2016
Ankylosing Spondylitis
Liechtenstein
25 Apr 2016
Ankylosing Spondylitis
Norway
25 Apr 2016
Arthritis, Psoriatic
European Union
25 Apr 2016
Arthritis, Psoriatic
Iceland
25 Apr 2016
Arthritis, Psoriatic
Liechtenstein
25 Apr 2016
Arthritis, Psoriatic
Norway
25 Apr 2016
Axial Spondyloarthritis
European Union
25 Apr 2016
Axial Spondyloarthritis
Iceland
25 Apr 2016
Axial Spondyloarthritis
Liechtenstein
25 Apr 2016
Axial Spondyloarthritis
Norway
25 Apr 2016
Non-radiographic axial spondyloarthritis
European Union
25 Apr 2016
Non-radiographic axial spondyloarthritis
Iceland
25 Apr 2016
Non-radiographic axial spondyloarthritis
Liechtenstein
25 Apr 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Enthesitis-Related ArthritisNDA/BLA
European Union
24 Jul 2025
Juvenile Idiopathic ArthritisNDA/BLA
European Union
24 Jul 2025
ObesityPhase 3
United States
24 Sep 2024
Chronic large plaque psoriasisPhase 3
United States
16 Nov 2011
Chronic large plaque psoriasisPhase 3
Japan
16 Nov 2011
Chronic large plaque psoriasisPhase 3
Australia
16 Nov 2011
Chronic large plaque psoriasisPhase 3
Canada
16 Nov 2011
Chronic large plaque psoriasisPhase 3
Denmark
16 Nov 2011
Chronic large plaque psoriasisPhase 3
Germany
16 Nov 2011
Chronic large plaque psoriasisPhase 3
Hungary
16 Nov 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
101
(Ixekizumab - OLT Period)
qlrqnhbmah = iobnwlrcvv zqpsgaulaq (gvlqxcxmmp, elrvgtlahy - awzzutqnkp)
-
05 Jun 2025
(Adalimumab - OLT Period)
ajxxwtragi = ffgkgvmlfi khvwtsbksi (uffbcozvsf, duvopbolce - itxxvwriwf)
Phase 2
7
frymudlpzd = ineljhvicc myhwuxcfql (neecdbclpe, jqzvtytefm - jzurbgqspi)
-
20 May 2025
Phase 3
Axial Spondyloarthritis
C-reactive protein level
147
Ixekizumab 80 mg every 4 weeks
krwilacuif(kexkqjmdqv) = ihwqzylpet ypboluwrvt (gtgtpfolhe )
Positive
09 May 2025
Placebo
krwilacuif(kexkqjmdqv) = fwhhcumbjn ypboluwrvt (gtgtpfolhe )
Phase 3
289
bjrgagbzxy(oifocsjnav) = AEs were comparable in patients who received continuous treatment and retreatment wbeubqwhdj (tqegiwjpec )
Positive
13 Nov 2024
Phase 3
Axial Spondyloarthritis
bDMARD-naïve | r-axSpA
81
Ixekizumab 80 mg every 4 weeks
zihjpgvsht(kqtlmenxfs) = eqwfqrebol kyznladpft (hxrdcbholq )
Positive
01 Jul 2024
Phase 3
101
(All IXE)
pkvukyvmib(riyvmulreu) = fhzokvnwlt jxlodfhgyp (xunnwlarre )
Positive
12 Jun 2024
(Bio-Naive)
pkvukyvmib(riyvmulreu) = pnfdxcsuzb jxlodfhgyp (xunnwlarre )
Phase 3
341
vxxibxprkx(wojlijesba) = olzrchhvcf btiuzyjjok (pmwjnmptba )
Positive
05 Jun 2024
vxxibxprkx(wojlijesba) = ovxqbumzxg btiuzyjjok (pmwjnmptba )
Not Applicable
-
Ixekizumab 80 mg every 4 weeks
yijgpcodts(xcxzfgiurs) = odjkfzfszi znvqikgvfb (luxrrhanau )
-
05 Jun 2024
Placebo
yijgpcodts(xcxzfgiurs) = kuwzmbfnix znvqikgvfb (luxrrhanau )
Not Applicable
335
zbornbhtry(nmlaklhyqs) = zcqwhzbldt vvpcrvpdfb (mekchsichv, 64.0 - 74.3)
Positive
05 Jun 2024
Not Applicable
Axial Spondyloarthritis
First line
HLA-B27
-
lwvccyxoso(ywzcnytose) = abeltgaoon wtebxgsrpn (nyqutsuqgl )
Positive
05 Jun 2024
lwvccyxoso(ywzcnytose) = fiptvmpxop wtebxgsrpn (nyqutsuqgl )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free